178 related articles for article (PubMed ID: 23756616)
1. Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.
Hill JW; Shreay S; McGarvey N; De AP; Hess GP; Corey-Lisle PK
Support Care Cancer; 2013 Nov; 21(11):2957-65. PubMed ID: 23756616
[TBL] [Abstract][Full Text] [Related]
2. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
3. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
Berger A; Edelsberg J; Kallich J; Oster G
Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
[TBL] [Abstract][Full Text] [Related]
4. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
Polsky D; Eremina D; Hess G; Hill J; Hulnick S; Roumm A; Whyte JL; Kallich J
Pharmacoeconomics; 2009; 27(9):755-65. PubMed ID: 19757869
[TBL] [Abstract][Full Text] [Related]
5. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
6. Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy.
Berger A; Lord C; Corey-Lisle PK; Williams GR; Oster G
Clin Ther; 2012 Jun; 34(6):1350-63. PubMed ID: 22591754
[TBL] [Abstract][Full Text] [Related]
7. Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.
Reitan JF; van Breda A; Corey-Lisle PK; Shreay S; Cong Z; Legg J
Clin Drug Investig; 2013 May; 33(5):383-9. PubMed ID: 23553358
[TBL] [Abstract][Full Text] [Related]
8. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia.
Steensma DP; Dakhil SR; Novotny PJ; Sloan JA; Johnson DB; Anderson DM; Mattar BI; Moore DF; Nikcevich D; Loprinzi CL
Am J Hematol; 2015 Oct; 90(10):877-81. PubMed ID: 26149465
[TBL] [Abstract][Full Text] [Related]
10. Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia.
Muller RJ; Baribeault D
Am J Health Syst Pharm; 2007 Dec; 64(24):2547-56. PubMed ID: 18056942
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
[TBL] [Abstract][Full Text] [Related]
12. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
[TBL] [Abstract][Full Text] [Related]
14. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
Tunceli O; Bailey RA; Stephenson JJ; Singer J
J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
[TBL] [Abstract][Full Text] [Related]
15. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
Schwartzberg L; Burkes R; Mirtsching B; Rearden T; Silberstein P; Yee L; Inamoto A; Lillie T
BMC Cancer; 2010 Oct; 10():581. PubMed ID: 20973982
[TBL] [Abstract][Full Text] [Related]
16. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
17. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Henry DH; Dahl NV; Auerbach MA
Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
[TBL] [Abstract][Full Text] [Related]
19. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
Patton J; Reeves T; Wallace J
Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]